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ABSTRACT 
Regarding the role of TNFα in the induction of hyperalgesia, the dual suggested roles of the 
Pp38 MAPK intracellular pathway in the emergence of symptomatic inflammation, we aimed 
to investigate the bidirectional effects of serum TNFα level and p38 MAPK phosphorylation 
on hyperalgesia variation during different stages of adjuvant-induced arthritis. Hyperalgesia 
and edema were assessed at 0, 3, 7, 14, and 21 days of study after arthritis induction by CFA. 
Anti-TNFα and Pp38 inhibitor were administered during the 21 days of study. Receptor and 
intra-cellular enzyme expression were detected by western blotting. Anti-TNFα administra-
tion in the AA group decreased paw volume and hyperalgesia until the 14th day of study; on 
the 21st day, those symptoms increased. Daily administration of anti-TNFα antibody caused 
significant decrease in spinal mOR protein and Pp38/p38 MAPK enzyme level expression on 
the 14th and 21st days compared to the AA control group. Our data suggested that phosphory-
lation of spinal p38 MAPK enzyme played an important role in bidirectional effects of serum 
TNFα on inflammatory symptoms via spinal mOR expression variation. 
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INTRODUCTION 
Inflammation is the primary and, essen-
tially, a salutary response that normally re-
solves with the restoration of normal tissue 
structure and function; however, when in-
flammation persists (chronic inflammation), 
it can cause tissue damage and loss of func-
tion (Rodriguez-Vita and Lawrence, 2010). 
It results in rapid elevation of the secretion 
of inflammatory mediators, chemokines, 
and cytokines, such as interleukins 1 and 6 
(IL-1 and IL-6), and tumour necrosis fac-
tors α (TNFα) (Zaringhalam et al., 2010). 
Pain and disability are the principal clinical 
features of inflammation. This situation is 
associated with sensitisation of specialised 
sensory neurons that comprise the nocicep-
tive (pain) pathway (Inglis et al., 2005). 
Rheumatoid arthritis (RA) is the most 
common form of inflammatory arthritis, 
characterised by chronic synovitis, progres-
sive joint damage, and significant pain dis-
ability. Although the etiology of RA re-
mains elusive, there is evidence that cyto-
kines play a critical role in its pathogenesis 
(Garfield et al., 2005). Complete Freund’s 
adjuvant (CFA) has been utilised to induce 
an arthritic immunopathological disease 
that displays many of the pathological fea-
tures of human RA. This arthritis model has 
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been used extensively, not only to analyse 
the cellular and molecular aspects of RA, 
but also to evaluate the anti-inflammatory/ 
anti-nociceptive effects of newly developed 
drugs on chronic arthritis (Lee et al., 2009). 
The use of biological therapies targeting 
these key pro-inflammatory molecules and 
their receptors has emerged as a powerful 
tool for the control of many systemic in-
flammatory disorders in the last few years 
(Garfield et al., 2005). TNFα is a potent cy-
tokine that exerts pleiotropic functions in 
immunity, inflammation, control of cell 
proliferation, differentiation, and apoptosis 
(Caminero et al., 2011). TNFα is a key cy-
tokine involved in the pathogenesis of RA, 
resulting in a chronic inflammatory state in 
which the synovial membrane is the prima-
ry site of attack. Therapies directed against 
tumour necrosis factor (TNF) are effective 
for treatment of rheumatoid arthritis and 
reduced pain scores associated with this 
condition (Inglis et al., 2005). However, the 
precise molecular mechanisms by which 
TNFα exerts its destructive effect in RA are 
not known, and the mechanisms by which 
TNFα antagonists exert their therapeutic 
effect are not completely understood (Gar-
field et al., 2005). TNFα signalling involves 
various pathways and signalling molecules, 
and this makes it an interesting and com-
plex process to investigate. The binding of 
TNFα to its receptors initiates a cascade of 
events involving the activation of a series of 
mitogen-activated protein kinase kinase 
(MAP2K) that further phosphorylates and 
activates a dual-specificity protein kinase 
(MEK). This, in turn, activates a mitogen-
activated protein (MAP) kinase (e.g. p38 
MAPK); then, activated p38 MAPK phos-
phorylates downstream kinases. Measuring 
levels of phosphorylated p38 (i.e. Pp38) 
often provides a measure of cellular re-
sponses to inflammation (Zhang et al., 
2008). Pp38 MAPK is primarily activated 
within cells involved in the inflammatory 
process, which in turn induces the synthesis 
of key inflammatory mediators, such as 
TNFα, IL-1, IL-6, and IL-8; this production 
can play a key role in the pathogenesis of 
many chronic inflammatory disorders, such 
as RA (Cuenda and Rousseau, 2007). 
Moreover, it is clear that sustained inflam-
mation causes physiological and pharmaco-
logical changes in the pain inhibitory sys-
tem, and that increases in the potency of 
opioid agonists alleviate hyperalgesia dur-
ing inflammation. Opioid receptors are in-
volved in the pain mandatory system during 
inflammation, and the µ-opioid receptor 
(mOR) is the most commonly associated 
with analgesic therapy in chronic pain 
(Martin et al., 2001). Our previous studies 
also indicated that decreased hyperalgesia 
during chronic inflammation was related to 
an increase in spinal mOR expression 
(Zaringhalam et al., 2008; Tekieh et al., 
2011). Scientists have established that 
p38MAPK also might play a key role in the 
variation of the expression of cellular plas-
ma membrane receptors during different 
stages of inflammation. Some studies have 
indicated that p38 MAPK enzyme activa-
tion modulates opioid receptor endocytosis 
(Mace et al., 2005). Therefore, regarding 
the role of TNFα in hyperalgesia induction 
via intra-cellular signalling pathways, the 
dual suggested roles of the p38 MAPK en-
zyme in the emergence of symptomatic in-
flammation, and the importance of develop-
ing effective and safer painkilling drugs 
with fewer side effects, we aimed to inves-
tigate the relationships among serum TNFα 
level, p38 MAPK enzyme activity, and hy-
peralgesia variation during different stages 
of CFA-induced arthritis in male Wistar 
rats. 
 
MATERIALS AND METHODS 
Laboratory animals 
Adult male Wistar rats, weighing 200–
220 g at the beginning of the experiments, 
were used in the present study. The animals 
were housed at a room temperature of 22.0 
± 1 °C with a 12 h light–dark cycle (lights 
on, 08:00 am to 8:00 pm). Food and water 
were available. The study protocol was ap-
proved by the local ethics committee for the 
use of animals in research, and we followed 
the guidelines of ethical standards for in-
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vestigation of experimental pain in animals 
(Zimmermann, 1983). 
 
Local paw inflammation induction 
A model of persistent inflammatory 
pain was produced by unilateral intraplantar 
injection of complete Freund’s adjuvant 
(CFA) (heat-killed and dried mycobacte-
rium Tuberculosis) in a volume of 100 µl 
into the plantar surface of the right hind 
paw (ipsilateral side) of rats under light an-
aesthesia with methoxy isoflurane. Control 
rats were given saline in a volume of 100 µl 
into the plantar surface of the right hind 
paw (Rezazadeh et al., 2009). 
 
Measurement of paw edema  
The intensity of inflammatory edema 
was measured on days 0, 3, 7, 14, and 21 
after the injection of CFA and other inter-
ventions. Paw swelling (edema) was as-
sessed by measuring the volume of the in-
jected hind paw by plethysmometer (model 
7141; Ugo Basile, Comerio, VA, Italy), be-
fore and after intervention. The results are 
expressed as the algebraic difference be-
tween the volume (ml) of the injected paw 
before CFA injection (day 0) and during 
different stages of study. All experiments 
were repeated three times, and the average 
per paw was determined (Bianchi et al., 
2008). 
 
Measurement of thermal hyperalgesia  
To assess sensitivity to thermal stimula-
tion, each of the rats’ hind paws was tested 
individually using a thermal stimulus appa-
ratus (Ugo Basilar; Verse, Italy). The inten-
sity of the thermal stimulus was adjusted to 
achieve an average baseline paw withdraw-
al latency of approximately 20–22 s in na-
ive rats. Only quick hind paw movements 
(with or without licking of the hind paws) 
away from the stimulus were considered a 
withdrawal response. Paw movements as-
sociated with locomotion or weight-shifting 
were not counted as a response. The paws 
were measured alternating between left and 
right, with an interval of more than 5 min 
between measurements (Narita et al., 2008). 
The mean latency of the withdrawal re-
sponses for each foot was calculated. Then, 
the value for the affected paw (CFA-
injected paw) was subtracted from that of 
the other paw, and the result was consid-
ered the hyperalgesia sign in the injured 
paw (Tekieh et al., 2011). 
 
Blood sampling and serum TNFα  
measurements 
The serum TNFα levels of the rats were 
assayed by a rat standard ELISA kit (Koma 
Biotech, Seoul, Korea) on day 0 (before 
CFA injection) and at different phases of 
study according to the manufacturer’s pro-
tocol. The rats were lightly anaesthetised 
and retro-orbitally bled into heparinised 
tubes. The samples were centrifuged and 
stored at -80 °C. The collected serum 
showed 100 % cross-reactivity with the 
ELISA kit (Zaringhalam et al., 2010). 
 
Chemicals and reagents 
To evaluate further the roles of TNFα 
and Pp38 MAPK in inflammatory symp-
toms, the rats were treated with TNFα anti-
body and p38 MAPK phosphorylation in-
hibitor to deplete serum TNFα and Pp38 
levels. The anti-rat TNFα antibody was ob-
tained from Abcam/CA (# ab9755), and the 
Pp38 MAPK inhibitor, SB203580, was pur-
chased from Promega/USA. According to 
the manufacturer, the neutralisation dose 50 
(ND50) for this anti-rat TNFα antibody was 
approximately 0.145–0.165 µg/ml in the 
presence of 2.0 ng/ml rat TNFα. SB203580 
(p38 MAPK inhibitor) re-suspended 1 mg 
in 265 μl of vehicle to produce a stock solu-
tion of 10 mM; for inhibition of p38 phos-
phorylation, 70 nM/100 µM of that stock 
was administered via I.P. on a daily basis 
(Zaringhalam et al., 2010). The anti-TNFα 
neutralising antibody and SB203580 were 
dissolved in sterile phosphate-buffered sa-
line (PBS), and the control animals received 
only PBS as a vehicle. The primary anti-
bodies—p38 MAPK antibody (#ab31828), 
phospho-p38 MAP Kinase (Thr180Tyr182) 
antibody (#ab32557), and mOR antibody 
(#ab10275) were obtained from Abcam/ 
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UK. Other reagents were all of analytical 
grade. All solutions were prepared fresh a 
maximum of 30 min prior to injection and 
were equilibrated at room temperature. 
 
Western blot analysis 
After behavioural tests, western blot 
was used to examine the variations of spinal 
mOR, p38 MAPK, and Pp38 MAPK en-
zyme expression detection during different 
stages of study. Briefly, the lumbar spinal 
cord was quickly removed after the rat was 
decapitated, and homogenised in RIPA 
buffer containing 50 mM Tris-HCL 
(pH 7.4), 1mM EDTA, NP40 1 %, NaCl 
150 mM, aprotinin 10 mg/ml, leupeptin 
1 µl, and PMSF 2 mM. Equal amounts of 
proteins (50 μg) were loaded on 10 % sodi-
um dodecyl sulphate – polyacrylamide gel 
electrophoresis (SDS-PAGE) gels and run 
at 100mv for approximately 1 h. Proteins 
were transferred to Immobilon-P PVDF 
membranes (Millipore, Bedford, MA) using 
mini-PROTEAN II (Bio-Rad) at 100 V for 
80 min. Nonspecific binding sites on the 
membrane were blocked by incubation 
(90 min at 24 °C or overnight at 4 °C) in 
blocking buffer (0.2 % Aurora Blocking 
Reagent; 1X Phosphate Buffered Saline: 
0.058 M Na2HPO4, 0.017 M NaH2PO4, 
0.068 M NaCl; 0.05 % Tween-20 from ICN 
Biomedicals, Costa Mesa, CA) followed by 
incubation (1 h, 24 °C) with primary anti-
bodies in blocking buffer (rabbit polyclonal 
mOR, rabbit monoclonal SB203580, and 
mouse monoclonal SB203580 (1:1000; 
Abcam plc UK). The membranes were 
washed twice with blocking buffer and then 
incubated (1 h, 24°C) with secondary anti-
bodies in blocking buffer (anti-rabbit and 
anti-mouse IgG [1:10000; Abcam]). They 
were then washed three times with blocking 
buffer, followed by two quick rinses with 
assay buffer (20 mM Tris-HCl, pH 9.8, 
1 mM MgCl2). The immunoreactivity of the 
proteins on the membranes was visualised 
using a chemiluminescence detection sys-
tem (ECL, Amersham). The membranes 
were then incubated in stripping buffer 
(100 μM 2-mercaptoethanol, 2 % SDS, 
62.5 mM Tris [pH 6.7]) at 50 °C for 30 min 
and reprobed with beta-actin primary anti-
body (1:5000; Cell Signalling) as a loading 
control. Band intensity was measured den-
sitometrically using NIH Image (1.60) and 
expressed as the ratio of the intensity of the 
mOR band to that of β-actin; Pp38 MAPK 
band to p38 MAPK to account for any dif-
ferences in starting spinal mOR and phos-
phorylated p38 MAPK enzyme proteins, 
respectively. Each experiment was replicat-
ed three times with new groups of rats (Ku-
rien and Scofield, 2006). 
 
Experimental procedure  
To recognise the effect and relation of 
serum TNFα level and Pp38 MAPK en-
zyme on inflammation, after single local 
hind paw CFA injection and ipsilateral paw 
inflammation induction, anti-TNFα anti-
body and p38 phosphorylation inhibitor, 
SB203580, were administered daily from 
day 0 to day 21 of the study. Behavioural 
tests, blood TNFα level assessment, and 
spinal protein expression variation detec-
tion were made during the different phases 
of inflammation (Zaringhalam et al., 2008), 
at 0 (before CFA injection), 3, 7, 14, and 21 
days. To achieve these different time point 
measurements during this study, different 
experimental groups (as control and exper-
imental groups) were identified - each ex-
perimental group was comprised of six 
adult rats. At the end of each session in 
each study group, the animals were deeply 
anaesthetised and decapitated; then, the 
lumbar spinal cords were quickly removed 
on iced saline and stored at -80 ºC until se-
lected protein detection was conducted by 
western blotting. 
 
Statistical analysis 
Results are presented as the mean 
± SEM. Data was analysed by one-way 
analysis of variance (ANOVA), followed 
by Tukey’s test for multiple comparison. 
Unpaired Student’s t-test was used to de-
termine significant differences between the 
groups. An effect was determined to be sig-
nificant if the p-value was less than 0.05. 
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RESULTS 
Variation of serum TNFα levels during 
different stages of study 
To determine the magnitude of change 
following a CFA-induced inflammation, 
and the role of some mediators in this pro-
cess, serum TNFα concentrations were ex-
amined by rat-specific ELISA kit. A re-
markable increase in TNFα concentration 
after CFA treatment was observed. Serum 
TNFα levels significantly increased on the 
3rd, 7th, 14th, and 21st days, compared to 
day 0, in the AA rats (p<0.001). Our find-
ings revealed that continuation of inflam-
mation caused significant decreases in 
TNFα levels on the 14th and 21st days, 
compared to the 3rd and 7th days of the 
study (p<0.001); however, they were higher 
than on day 0 (p<0.001). Anti-TNFα ad-
ministration in the AA rats returned serum 
TNFα levels to those of day 0 (before CFA 
injection), and the AA+ anti-TNFα rats in-
dicated a significant reduction in serum 
TNFα levels compared to the same days in 
the AA group (p<0.001). Moreover, block-
ing of p38 MAPK enzyme phosphorylation 
by SB203580 caused a significant reduction 
in serum TNFα levels on the 7th, 14th, and 
21st days in the AA rats, compared with the 
AA control group (p<0.05, p<0.01, and 
p<0.01, respectively). In the AA rats, serum 
TNFα levels decreased significantly on 
days 14 and 21 of the study, compared to 
day 7 (p<0.05). There was no significant 
difference in TNFα level between days 0 
and 3 during the administration of the p38 
MAPK enzyme activity inhibitor (Figure 
1).  
 
Paw volume variation due to long-term 
anti-TNFα administration in AA rats 
CFA injection into the right hind paw 
caused a marked increase in paw volume 
(edema). Right injected paw volume 
showed significant increase on days 3, 7, 
14, and 21 after CFA injection compared to 
day 0 in the AA control group (p<0.001). 
Our results indicated that CFA-injected paw 
volume was significantly reduced by anti-
TNFα administration on days 3, 7, and 14 
compared to the same days in the AA con-
trol group (p<0.001). Paw volume in the 
AA+ anti-TNFα group on the 21st day was 
not only significantly greater than that of 
the AA control group (p<0.01), but also 
significantly greater than the previous days 
in the same group (p<0.001). Furthermore, 
our data showed that SB203580 administra-
tion during 21 days after CFA injection 
caused a meaningful decrease in paw vol-
ume on the 3rd, 7th, 14th, and 21st days 
(Figure 2). There were no significant differ-
ences in paw volume variation between the 
AA+ PBS group (as vehicle) and the AA 
control group (data not shown). 
 
Figure 1: ELISA analysis of serum TNFα level 
during different stages of CFA-induced inflam-
mation. A significant decrease of serum TNFα 
levels were observed in AA+ anti–TNFα and 
AA+ SB203580 groups. Data are presented as 
mean ± S.E.M (n=6/group). *** p<0.0001: For 
comparing the variation of serum TNFα level 
between different days of study with day 0.  
++ p<0.001, + p<0.01: Comparison of serum 
TNFα level between AA and AA+ SB203580 
rats. AA: adjuvant-induced arthritis; SB203580: 
p38 MAPKinases inhibitor 
 
Thermal hyperalgesia variation due to 
long-term anti-TNFα administration in 
AA rats 
The CFA-injected rats displayed vary-
ing degrees of thermal hyperalgesia in the 
injected paw during different stages of AA. 
Hyperalgesia significantly increased on 
days 3 and 7 after CFA injection compared 
to day 0 in the AA control group (p<0.001). 
Our results also indicated that inflammation 
continuation caused hyperalgesia to de-
crease on days 14 and 21, compared with 
days 3 and 7 (p<0.001). Moreover, there 
was a significant decrease of hyperalgesia 
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on day 21 of the study compared to day 14 
in the AA control group (p< 0.001). Anti-
hyperalgesic effects of daily TNFα anti-
body neutralising dose administration in the 
AA rats had been seen in the first week of 
the study, but this effect reversed on the 
14th and 21st days after CFA injection. 
Thermal hyperalgesia declined significantly 
with daily anti-TNFα antibody administra-
tion on the 3rd  and 7th days of intervention 
in the AA+ anti-TNFα group compared to 
the same days in the AA control group 
(p<0.001 for both). Furthermore, long-term 
daily neutralising doses of TNFα antibody 
treatment caused a significant increase in 
hyperalgesia on days 14 and 21 of the study 
in the AA+ anti-TNFα  group compared 
with the same days in the AA control group 
(p<0.001 for both). SB203580 administra-
tion during 21 days of study caused a sig-
nificant decrease of hyperalgesia on the 7th 
day of this study; however, long-term daily 
administration caused a reversal of this ef-
fect on the 21st day and remarkably in-
creased thermal hyperalgesia (Figure 3). In 
addition, no significant discrepancy was 
identified between the AA+ PBS group and 
the AA control group (data not shown). 
 
 
 
 
 
 
 
 
 
Figure 2: Paw edema variation due 
to anti-TNFα antibody and 
SB203580 administration during 21 
days of CFA-induced inflammation, 
which was assessed by ple-
thysmometer. Data are expressed 
as mean ± S.E.M (n=6/group). 
*** p<0.001: For comparing of paw 
volume variations between different 
days of study and day 0 in AA rats. 
†† p<0.001, † p<0.01: Comparison 
of paw volume variation between AA 
and AA+ anti-TNFα antibody treated 
rats. ‡‡‡ p<0.0001: Comparison of 
paw variation between AA and AA+ 
SB203580 treated rats. AA: adju-
vant-induced arthritis; SB203580: 
p38 MAPKinases inhibitor 
Figure 3: Anti-TNFα antibody and 
SB203580 administration caused sig-
nificant variation on CFA-induced hy-
peralgesia during 21 days. Data are 
expressed as mean ± S.E.M 
(n=6/group). *** p<0.0001: For com-
paring the hyperalgesia variation be-
tween day 0 and other days in AA 
rats. ‡‡‡ p<0.0001: For comparing 
hyperalgesia variations between AA 
and AA+ anti-TNFα antibody treated 
groups. ††† p<0.0001, †† p<0.001: 
For comparing hyperalgesia varia-
tions between AA and AA+ SB203580 
treated groups. AA: adjuvant-induced 
arthritis; SB203580: p38 MAPKinases 
inhibitor 
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Spinal mOR expression variation due to 
long-term anti-TNFα antibody administra-
tion in AA rats 
In order to check mOR protein expres-
sion in the lower back part of the spinal 
cords of the experimental groups, we used 
polyclonal antibody to detect mOR protein 
in the spinal cord. Analysis by densitometry 
showed that AA time-dependently caused a 
significant increase in spinal mOR protein 
expression when compared with the control 
group; in addition, there was no considera-
ble increase in spinal mOR expression until 
the 7th day of inflammation in the AA 
group, compared to day 0 (Figure 4A, B, C). 
 
 0 3 7 14 21 days 
 
mOR expression (48KDa) 
 
Beta actin (43KDa) 
 0 3 7 14 21 days 
 
mOR expression (48KDa) 
 
Beta actin (43KDa) 
 0 3 7 14 21 days 
 
mOR expression (48KDa) 
 
Beta actin (43KDa) 
Figure 4A, B, C: Immunoblots of mOR extract-
ed from the lower back part of spinal cords, 
which normalised to beta actin during different 
stages of study (days 0, 3, 7, 14, 21). A: Varia-
tion of lower back spinal mOR expression dur-
ing different days in AA, B: Variation of lower 
back spinal mOR expression during different 
days in AA+ SB203580 group C: Variation of 
lower back spinal mOR expression during dif-
ferent days in AA+ anti-TNFα group. AA: adju-
vant-induced arthritis; SB203580: p38 MAP-
Kinases inhibitor 
Our results confirm that, on the lower 
back part of the spinal cords obtained from 
the AA rats, spinal mOR protein expression 
observably increased on days 14 and 21 
compared to day 0 of the study (p<0.001). 
On day 21 day of AA treatment, spinal 
mOR protein expression increased signifi-
cantly higher from day 14 (p<0.01). Daily 
administration of anti-TNFα antibody in the 
AA rats caused a significant decrease in 
spinal mOR protein expression on the 14th 
and 21st days of the study compared with 
the AA control group (p<0.001). Compari-
son of spinal mOR protein expression be-
tween the AA+ anti-TNFα and AA control 
groups indicated that mOR expression de-
crease was significantly higher on day 21 
compared with day 14 (p<0.001) (Figure 5). 
Our data also showed that the ratio of spinal 
mOR protein band intensity in the AA+ 
SB203580 group significantly decreased on 
days 14 and 21 compared with the AA con-
trol group (p<0.001 for both). The decrease 
of spinal mOR protein band intensity in the 
AA+ SB203580 group on day 21 was sig-
nificantly higher than on day 14 (p<0.001) 
(Figure 6). PBS administration (as a vehi-
cle) in the AA rats did not alter spinal mOR 
protein expression compared with the AA 
control group (data not shown). 
 
Spinal mOR expression variation due to 
long-term anti-Pp38 MAPK enzyme anti-
body administration in AA rats 
For the sake of investigative quantity of 
Pp38 MAPK enzyme activity in the lower 
back part of the spinal cord, we utilised a 
monoclonal antibody that detected the Pp38 
MAPK enzyme. Afterward, the data was 
explained by densitometry (Figure 7A, B, 
C). Our data showed that in the lower back 
segment of the spinal cords obtained from 
the AA rats, p38 MAPK enzyme phosphor-
ylation was noticeably raised during differ-
ent days of study. Pp38 to p38  MAPK en-
zyme levels in the AA rats indicated signif-
icant increases on days 3, 7, 14, and 21, 
compared with day 0 (3rd day: p<0.01; oth-
er days: p<0.001). However, the levels of 
phosphorylated p38 MAPK enzyme in-
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creased on days 14 and 21 compared with 
day 0 in the AA rats; however, this increase 
was significantly higher on the 21st day 
(p<0.01). Our results also showed that 
Pp38/p38 MAPK enzyme levels in the low-
er back segment of spinal cord of the AA+ 
anti-TNFα group significantly decreased on 
days 7, 14, and 21 of the study compared 
with the AA control group (p<0.01, 
p<0.001, p<0.001, respectively). The de-
crease in Pp38/p38MAPK enzyme levels on 
day 21 was significantly greater than on day 
14 when comparing between the AA+ anti-
TNFα and AA groups (p<0.001 for both) 
(Figure 8). PBS administration in the AA 
group as a vehicle of anti-TNFα antibody 
did not change p38 MAPK enzyme phos-
phorylation compared to the AA control 
group (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Anti-TNFα antibody ad-
ministration significantly reduced 
spinal mOR expression during dif-
ferent stages of AA. Data are pre-
sented as mean ± SEM 
(n=6/group). ***p<0.001 Compari-
son of ratio of spinal mOR protein 
band intensity between different 
days of AA. +++p<0.001: Compari-
son of spinal mOR protein band 
intensity variation between AA and 
AA+ anti-TNFα antibody treated rats 
on 14th  and 21st  days. ##p<0.01 
Comparison of spinal mOR protein 
band intensity variation in AA and 
AA+ anti-TNFα antibody treated rats 
between 14th and 21st days. AA: 
adjuvant-induced arthritis; TNFα: 
tumour necrosis factor α 
Figure 6: Effects of SB203580 ad-
ministration on spinal mOR expres-
sion. SB203580 administration sig-
nificantly reduced spinal mOR ex-
pression during different stages of 
AA. Data are presented as mean ± 
SEM (n=6/group). ***p<0.001 Com-
parison of ratio of spinal mOR pro-
tein band intensity between different 
days of AA. ††† p<0.001 Compari-
son of spinal mOR protein band 
intensity between different days in 
AA and AA+SB203580 treated rats. 
‡‡‡p<0.001 Comparison of spinal 
mOR protein band intensity be-
tween AA and AA+ SB203580 
treated rats. AA: adjuvant-induced 
arthritis; SB203580: p38 MAP-
Kinases inhibitor 
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Figure 7A, B, C: Immunoblots of Pp38 MAPK 
enzyme extracted from the lower back part of 
spinal cord, which normalised to p38 MAPK 
enzyme during different stages of study (days 
0, 3, 7, 14, 21). A: Variation of Pp38 MAPK en-
zyme expression in AA rats. B: Variation of 
Pp38 MAPK enzyme expression in AA+ anti-
TNFα rats. C: Variation of Pp38 MAPK enzyme 
(38KDa) expression in AA+ SB203580 rats. AA: 
adjuvant-induced arthritis; SB203580: p38 
MAPKinases inhibitor; TNFα: tumour necrosis 
factor α 
 
 
 
 
 
DISCUSSION 
Coordination between the immune and 
nervous systems is essential for managing 
and modulating the immune neurobiologi-
cal responses to inflammation (Zöllner et 
al., 2003). It is clear that cytokines are in-
volved in different stages of inflammation 
by inducing time-dependent pro-/anti-
inflammatory effects. TNFα is a key pro-
inflammatory cytokine involved in the 
pathogenesis of RA (Bingham, 2002). 
Some studies suggest that therapy with anti-
TNFα agents provides a marked improve-
ment in patients with RA (Baumgartner, 
2004). However, our results demonstrated 
that long-term (21 days) anti-TNFα admin-
istration can elevate hyperalgesia during 
chronic CFA-induced arthritis.  
In the first phase of this study, our re-
sults indicated that the CFA-injected paw 
was typified by a rapid onset of inflamma-
tion evident within 24 h that continued to 
increase up to day 21. The findings, in 
agreement with others, not only indicated 
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Figure 8: Anti-TNFα antibody and 
SB203580 administration signifi-
cantly decreased p38 MAPK en-
zyme phosphorylation during differ-
ent stages of AA. Data are present-
ed as mean ± SEM (n=6/group). 
***p<0.001: Comparison of ratio of 
Pp38/p38 MAPK enzyme band in-
tensity between different days of AA 
with day 0. ++p<0.001: Comparison 
of Pp38/p38 MAPK enzyme band 
intensity between different days of 
study and day 0 in AA+ anti-TNFα 
antibody treated rats. ###p<0.001: 
Comparison of Pp38/p38 MAPK 
enzyme protein band intensity be-
tween AA+ SB203580 and AA+ an-
ti-TNFα antibody treated rats. AA: 
adjuvant-induced arthritis; 
SB203580: p38 MAPKinases inhibi-
tor; TNFα: tumour necrosis factor α. 
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an increase of serum TNFα levels due to the 
CFA injection, but also indicated that the 
levels remain elevated until the 21st day 
after CFA intervention. A number of stud-
ies have documented that CFA-induced 
mono-arthritis has two phases; in the first 
phase (inflammatory phase), an increase in 
pro-inflammatory cytokines, such as IL-1β, 
IL-6, and TNFα secretion, cause hyperalge-
sia and edema. The pro-inflammatory cyto-
kine TNFα is a systemic marker of inflam-
mation (Zaringhalam et al., 2010). In acute 
situations, TNFα has been reported to sensi-
tise nociceptive neurons indirectly via the 
induction of a pro-inflammatory cytokine 
cascade involving IL-1β, IL-6, and IL-8, 
resulting in the release of prostaglandins 
and other mediators from immune cells 
(Hackett et al., 2008). Furthermore, the ap-
plication of TNFα enhances calcium cur-
rents and increases neuron sensitivity to the 
neurotoxin capsaicin in cultures of sensory 
neurons (Khan et al, 2008). Thus, the anti-
hyperalgesia and anti-inflammatory effects 
of anti-TNFα antibody administration dur-
ing the acute phase of CFA-induced in-
flammation were expected, as they were 
mentioned by some other studies.  
Chronic inflammation in arthritis is 
driven by a variety of pro-inflammatory cy-
tokines, chemokine, and other mediators 
that outnumber or outperform their anti-
inflammatory counterparts (Choy and Pa-
nay, 2001). CFA-induced arthritis is the 
most widely used chronic model in which 
the physiological and pathological changes 
are comparable with those seen in human 
rheumatoid arthritis (Möller and Villiger, 
2006). Although the chronic phase of this 
study (arthritic phase) is manifested as a 
progressive increase in the volume of the 
injected paw, hyperalgesia significantly de-
creased compared to the acute phase. The 
long-term administration of anti-TNFα neu-
tralising doses in this study also enhanced 
hyperalgesia in CFA-injected rats. Previous 
studies have reported the significant effica-
cy of anti-TNFα antibody Etanercept treat-
ment of inflammatory symptoms in short-
term studies (Brandt et al., 2004). It has 
been shown that the transition from acute to 
chronic inflammation is likely to involve 
several systems, including changes in cyto-
kine signalling, both centrally and peripher-
ally; however, the mechanisms involved in 
these changes are poorly understood. Re-
cent studies indicate that chronic inflamma-
tion is associated with physiological and 
pharmacological changes in the pain inhibi-
tory system. The analgesic effects of pe-
ripherally applied opioids are augmented 
under conditions of tissue injury and in-
flammation. Our previous studies clarified 
the important role of spinal mOR expres-
sion increase on hyperalgesia decrease dur-
ing the chronic phase of inflammation, 
which was blocked by naloxone (Zaringha-
lam et al., 2008). Assessment of long term 
anti-TNFα administration effects on spinal 
mOR expression by western blotting in this 
study showed a significant reduction of ex-
pression of these opioid receptors during 
chronic CFA-induced inflammation (14th 
and 21st days). It was presumed that an in-
crease of TNFα levels can change cellular 
peptide synthesis via different pathways, 
directly or indirectly (Medeiros et al., 
2010). TNFα signalling involves various 
pathways and signalling molecules, and this 
makes it an interesting and complex process 
to investigate. It has been reported that ele-
vated level of TNFα increased extracellular 
regulated kinases and MAPK phosphoryla-
tion. In addition, recent studies indicate that 
phosphorylation of p38MAPK was de-
creased in response to TNFα inhibitors. 
Consistent with some studies, our findings 
showed that spinal Pp38 MAPK enzyme 
levels increased during CFA inflammation, 
that the increase was related to serum TNFα 
levels, and that anti-TNFα administration 
led to a decrease of phosphorylation of spi-
nal p38 MAPK. On the other hand, MAPK 
signalling pathways, like ERK, p38, and 
JNK are involved in controlling cellular re-
sponses to many stimuli, and they play a 
particularly important role in responding to 
inflammation by triggering production of 
transiently expressed protein synthesis and 
protein processing. In line with this, our 
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results also indicate that long-term inhibi-
tion of p38 MAPK enzyme phosphorylation 
reduced spinal mOR expression during 
chronic-phase CFA-induced inflammation. 
Taken together, it seems that a long-term 
increase in serum TNFα level can have a 
direct effect on spinal mOR expression via 
p38 MAPK enzyme phosphorylation.  
     Furthermore, it has been shown that the 
biological responses induced by TNFα 
might be mediated by other cytokines, such 
as IL-6 and IL-10. Some of these cytokines 
have been shown to elicit both pro- and an-
ti-inflammatory effects. IL-6 was shown to 
induce analgesia in an animal model of in-
flammation by contributing to the activation 
of the endogenous opioid system, which is 
induced in response to peripheral inflamma-
tion (Zöllner et al., 2003). Our previous 
study also revealed that administration of 
anti-IL-6 antibody causes hyperalgesia by 
decreasing spinal mOR expression during 
the chronic phase of CFA-induced inflam-
mation. Therefore, it is predictable that 
long-term anti-TNFα administration, by de-
creasing the secretion and activation of pro-
/anti-inflammatory cytokines, such as IL-6, 
may change spinal mOR expression, and 
via that effect on hyperalgesia, variation 
during chronic CFA-induced inflammation. 
In summary, this study confirmed the time-
dependent and bidirectional effects of se-
rum TNFα level on CFA-induced hyperal-
gesia, at least part of which may be mediat-
ed via spinal mOR expression variation. 
Our data also suggest that phosphorylation 
of p38 MAPK enzyme plays an important 
role in serum TNFα effects on mOR ex-
pression, which is inhibited by anti-TNFα 
and SB203580. Therefore, it seems that 
passing the initiating factors in human 
rheumatoid arthritis and manipulating the 
cytokine balance may be an effective thera-
peutic means by which chronic inflamma-
tion can be managed; however, this subject 
requires further investigation. 
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